Kazia Therapeutics Limited (KZIA) |
|
1 -0.01 (-0.99%)
|
01-27 15:58 |
|
Open: |
1 |
Pre. Close: |
1.01 |
|
High:
|
1.04 |
Low:
|
0.97 |
|
Volume:
|
32,193 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.22 One year: 1.43 |
| Support: |
Support1: 0.71 Support2: 0.5 |
| Resistance: |
Resistance1: 1.04 Resistance2: 1.22 |
| Pivot: |
0.97  |
| Moving Average: |
MA(5): 1  MA(20): 0.9
MA(100): 0.89 MA(250): 3.53 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 84.7 %D(3): 86.4 |
| RSI: |
RSI(14): 63.9 |
| 52-week: |
High: 8.6 Low: 0.5 |
| Average Vol(K): |
3-Month: 78 (K) 10-Days: 65 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KZIA ] has closed below upper band by 41.3%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.04 - 1.05 |
1.05 - 1.05 |
|
Low:
|
0.96 - 0.96 |
0.96 - 0.97 |
|
Close:
|
0.99 - 1 |
1 - 1.01 |
|
Company Description |
|
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. |
Headline News |
Fri, 27 Jan 2023
Kazia Therapeutics Limited (KZIA) Stock Price Today, Quote & News - Seeking Alpha
Tue, 17 Jan 2023
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers ... - Seeking Alpha
Mon, 16 Jan 2023
KAZIA ANNOUNCES PLACEMENT OF A$4.5MILLION AND ... - Marketscreener.com
Mon, 16 Jan 2023
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS - PR Newswire
Mon, 16 Jan 2023
KAZIA raises A$4.5M TO PROGRESS R&D PROGRAMS (NASDAQ ... - Seeking Alpha
Mon, 19 Dec 2022
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to ... - StreetInsider.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
1.195e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
180 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.291e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-248 |
|
Return on Assets (ttm)
|
657 |
|
Return on Equity (ttm)
|
-33.5 |
|
Qtrly Rev. Growth
|
10000 |
|
Gross Profit (p.s.)
|
-49.27 |
|
Sales Per Share
|
-43 |
|
EBITDA (p.s.)
|
4926.1 |
|
Qtrly Earnings Growth
|
-0.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.03 |
|
Price to Cash Flow
|
1.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
163330 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-07-13 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
